Literature DB >> 31620228

Novel Pyrazole-Containing Compounds Active against Mycobacterium tuberculosis.

Giovanna Poce1, Sara Consalvi1, Giulia Venditti1, Salvatore Alfonso2, Nicoletta Desideri1, Raquel Fernandez-Menendez2, Robert H Bates2, Lluis Ballell2, David Barros Aguirre2, Joaquin Rullas2, Alessandro De Logu3, Michelle Gardner4, Thomas R Ioerger5, Eric J Rubin4, Mariangela Biava1.   

Abstract

In this study, a series of 49 five-membered heterocyclic compounds containing either a pyridine- or a pyrrole-type nitrogen were synthesized and tested against Mycobacterium tuberculosis. Among them, only the 1,3,5-trisubstituted pyrazoles 5-49 exhibited minimum inhibitory concentration values in the low micromolar range, and some also exhibited an improved physicochemical profile without cytotoxic effects. Three pyrazoles were subjected to an animal tuberculosis efficacy model, and compound 6 induced a statistically significant difference in lung bacterial counts compared with untreated mice. Moreover, to determine the target of this series, resistors were generated, and whole genome sequencing revealed mutations in the mmpL3 gene.
Copyright © 2019 American Chemical Society.

Entities:  

Year:  2019        PMID: 31620228      PMCID: PMC6792160          DOI: 10.1021/acsmedchemlett.9b00204

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  18 in total

1.  Synthesis and biological evaluation of new enantiomerically pure azole derivatives as inhibitors of Mycobacterium tuberculosis.

Authors:  Daniele Castagnolo; Marco Radi; Filippo Dessì; Fabrizio Manetti; Manuela Saddi; Rita Meleddu; Alessandro De Logu; Maurizio Botta
Journal:  Bioorg Med Chem Lett       Date:  2009-02-28       Impact factor: 2.823

2.  Bactericidal activities of the pyrrole derivative BM212 against multidrug-resistant and intramacrophagic Mycobacterium tuberculosis strains.

Authors:  D Deidda; G Lampis; R Fioravanti; M Biava; G C Porretta; S Zanetti; R Pompei
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

3.  Activity of lipophilic and hydrophilic drugs against dormant and replicating Mycobacterium tuberculosis.

Authors:  Giovanni Piccaro; Giovanna Poce; Mariangela Biava; Federico Giannoni; Lanfranco Fattorini
Journal:  J Antibiot (Tokyo)       Date:  2015-05-06       Impact factor: 2.649

4.  Ligand-based virtual screening, parallel solution-phase and microwave-assisted synthesis as tools to identify and synthesize new inhibitors of mycobacterium tuberculosis.

Authors:  Fabrizio Manetti; Matteo Magnani; Daniele Castagnolo; Laura Passalacqua; Maurizio Botta; Federico Corelli; Manuela Saddi; Delia Deidda; Alessandro De Logu
Journal:  ChemMedChem       Date:  2006-09       Impact factor: 3.466

5.  Repurposing of a drug scaffold: Identification of novel sila analogues of rimonabant as potent antitubercular agents.

Authors:  Remya Ramesh; Rahul D Shingare; Vinod Kumar; Amitesh Anand; Swetha B; Sridhar Veeraraghavan; Srikant Viswanadha; Ramesh Ummanni; Rajesh Gokhale; D Srinivasa Reddy
Journal:  Eur J Med Chem       Date:  2016-07-09       Impact factor: 6.514

6.  Discovery of in vitro antitubercular agents through in silico ligand-based approaches.

Authors:  Daniela De Vita; Fabiana Pandolfi; Roberto Cirilli; Luigi Scipione; Roberto Di Santo; Laura Friggeri; Mattia Mori; Diego Fiorucci; Giorgio Maccari; Robert Selwyne Arul Christopher; Claudio Zamperini; Valentina Pau; Alessandro De Logu; Silvano Tortorella; Maurizio Botta
Journal:  Eur J Med Chem       Date:  2016-05-20       Impact factor: 6.514

Review 7.  MmpL3 Inhibitors: Diverse Chemical Scaffolds Inhibit the Same Target.

Authors:  Giovanna Poce; Sara Consalvi; Mariangela Biava
Journal:  Mini Rev Med Chem       Date:  2016       Impact factor: 3.862

8.  Pharmaceutical salt of BM635 with improved bioavailability.

Authors:  Giovanna Poce; Sara Consalvi; Martina Cocozza; Raquel Fernandez-Menendez; Robert H Bates; Fátima Ortega Muro; David Barros Aguirre; Lluis Ballell; Mariangela Biava
Journal:  Eur J Pharm Sci       Date:  2016-12-08       Impact factor: 4.384

9.  MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212.

Authors:  Valentina La Rosa; Giovanna Poce; Julio Ortiz Canseco; Silvia Buroni; Maria Rosalia Pasca; Mariangela Biava; Ravikiran M Raju; Giulio Cesare Porretta; Salvatore Alfonso; Claudio Battilocchio; Babak Javid; Flavia Sorrentino; Thomas R Ioerger; James C Sacchettini; Fabrizio Manetti; Maurizio Botta; Alessandro De Logu; Eric J Rubin; Edda De Rossi
Journal:  Antimicrob Agents Chemother       Date:  2011-10-24       Impact factor: 5.191

Review 10.  Drug-resistant tuberculosis: challenges and opportunities for diagnosis and treatment.

Authors:  Anastasia Koch; Helen Cox; Valerie Mizrahi
Journal:  Curr Opin Pharmacol       Date:  2018-06-06       Impact factor: 5.547

View more
  6 in total

1.  Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth.

Authors:  Peter C Ray; Margaret Huggett; Penelope A Turner; Malcolm Taylor; Laura A T Cleghorn; Julie Early; Anuradha Kumar; Shilah A Bonnett; Lindsay Flint; Douglas Joerss; James Johnson; Aaron Korkegian; Steven Mullen; Abraham L Moure; Susan H Davis; Dinakaran Murugesan; Michael Mathieson; Nicola Caldwell; Curtis A Engelhart; Dirk Schnappinger; Ola Epemolu; Fabio Zuccotto; Jennifer Riley; Paul Scullion; Laste Stojanovski; Lisa Massoudi; Gregory T Robertson; Anne J Lenaerts; Gail Freiberg; Dale J Kempf; Thierry Masquelin; Philip A Hipskind; Joshua Odingo; Kevin D Read; Simon R Green; Paul G Wyatt; Tanya Parish
Journal:  ACS Omega       Date:  2021-01-13

2.  Discovery of ( ±)-3-(1H-pyrazol-1-yl)-6,7-dihydro-5H-[1,2,4]triazolo[3,4-b][1,3,4] thiadiazine derivatives with promising in vitro anticoronavirus and antitumoral activity.

Authors:  Parameshwara Chary Jilloju; Leentje Persoons; Sathish Kumar Kurapati; Dominique Schols; Steven De Jonghe; Dirk Daelemans; Rajeswar Rao Vedula
Journal:  Mol Divers       Date:  2021-06-24       Impact factor: 2.943

Review 3.  MmpL3 Inhibition: A New Approach to Treat Nontuberculous Mycobacterial Infections.

Authors:  Jigar P Sethiya; Melanie A Sowards; Mary Jackson; Elton Jeffrey North
Journal:  Int J Mol Sci       Date:  2020-08-27       Impact factor: 5.923

4.  Identification of Novel Chemical Scaffolds that Inhibit the Growth of Mycobacterium tuberculosis in Macrophages.

Authors:  Sara Ahmed; Alyssa Manning; Lindsay Flint; Divya Awasthi; Yulia Ovechkina; Tanya Parish
Journal:  Front Pharmacol       Date:  2022-01-03       Impact factor: 5.988

5.  Nano-Based Drug Delivery Systems of Potent MmpL3 Inhibitors for Tuberculosis Treatment.

Authors:  Patrizia Nadia Hanieh; Sara Consalvi; Jacopo Forte; Gianluigi Cabiddu; Alessandro De Logu; Giovanna Poce; Federica Rinaldi; Mariangela Biava; Maria Carafa; Carlotta Marianecci
Journal:  Pharmaceutics       Date:  2022-03-10       Impact factor: 6.321

6.  Cryo-EM structure and resistance landscape of M. tuberculosis MmpL3: An emergent therapeutic target.

Authors:  Oliver Adams; Justin C Deme; Joanne L Parker; Philip W Fowler; Susan M Lea; Simon Newstead
Journal:  Structure       Date:  2021-07-08       Impact factor: 5.006

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.